AKTX - צמיחת מכירות משנה לשנה (TTM) Akari Therapeutics

Year-over-year sales volatility over a rolling 12-month period, where the current mark is 0.00, confirms the pricing power of Akari Therapeutics (AKTX) as the exclusive provider of rare immune drugs. Revenue stability is based on a streamlined international delivery system for orphan drugs. Business efficiency is further enhanced by the implementation of robotic screening and software automation for clinical data analysis to accelerate product time-to-market.
Akari Therapeutics PLC (AKTX) - פילוחי מדדים ודוחות פיננסיים

Akari Therapeutics (AKTX) is strengthening its position in the treatment of rare blood diseases through the efficacy of its complement inhibitors. This indicator measures trailing twelve-month revenue dynamics, neutralizing quarterly reporting gaps. The growth confirms the business's ability to monetize innovations and pass costs onto the market. Investors should remember that peak values often signal that an asset is overbought. By analyzing the trailing twelve-month (TTM) growth of operating sales revenue, one can objectively assess the sustainability of the business model.